Frassoldati A, Federico M, Barbieri F, Brausi M, Pollastri C, Berri G, Castagnetti G, Palladini P P, Silingardi V
Department of Medical Pathology, University of Modena, Italy.
Med Oncol Tumor Pharmacother. 1991;8(2):99-103. doi: 10.1007/BF02988861.
M-VEC (methotrexate, vinblastine, epidoxorubicin and cisplatin), a new combined drug regimen in which epidoxorubicin has been substituted to adriamycin to reduce the toxicity of the original M-VAC chemotherapy, has been tested in 23 patients with locally advanced transitional cell bladder cancer (TCBC) (stage T2-T4 No Mo). After two to four courses, an objective response was observed in 19 patients, with 13 clinical complete responses. Seven patients underwent cystectomy after chemotherapy: one patient had no residual tumor on bladder specimens, five patients had a surgical eradication of the disease, while one patient had only a partial resection. Eight relapses of bladder carcinoma were observed, three among the surgically treated patients and five among patients who did not undergo cystectomy, with a median time-to-relapse of 9.7 months. Progression-free survival at 24 months was 52.3%. M-VEC regimen appears to be effective in locally advanced TCBC, with acceptable toxicity.
M-VEC（甲氨蝶呤、长春碱、表柔比星和顺铂）是一种新的联合用药方案，其中表柔比星替代了阿霉素以降低原M-VAC化疗的毒性。该方案已在23例局部晚期移行细胞膀胱癌（TCBC）（T2-T4期，No Mo）患者中进行了测试。经过两到四个疗程后，19例患者出现客观缓解，其中13例临床完全缓解。7例患者在化疗后接受了膀胱切除术：1例患者膀胱标本无残留肿瘤，5例患者手术根除了疾病，而1例患者仅进行了部分切除。观察到8例膀胱癌复发，3例发生在接受手术治疗的患者中，5例发生在未接受膀胱切除术的患者中，中位复发时间为9.7个月。24个月时的无进展生存率为52.3%。M-VEC方案似乎对局部晚期TCBC有效，且毒性可接受。
